Cover Image

Does bladder outflow obstruction obfuscate the traditional clinical factors that are used to assess the risk of prostate cancer at rapid‐access diagnostic clinics?

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Thomas Philip Cahill, Samuel Joseph Withey, Steve Hazell, Declan Cahill, Netty Kinsella
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	BJUI Compass
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
by: Abel Tesfai, et al.
Published: (2024)

Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
by: Stijn M. van den Bosch, et al.
Published: (2026)

MRI performance to identify clinically significant prostate cancer following focal cryo‐ablation
by: Herbert Lepor, et al.
Published: (2025)

AI‐enhanced micro‐ultrasound improves detection of clinically significant prostate cancer at biopsy
by: Muhammad Imran, et al.
Published: (2026)

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection
by: Eric V. Li, et al.
Published: (2024)

A sustainable and expedited ‘One‐Stop’ prostate cancer diagnostic pathway to reduce environmental impact and enhance accessibility
by: Lorenzo Storino Ramacciotti, et al.
Published: (2024)

Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024)

Real‐world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience
by: Samantha Shekar, et al.
Published: (2025)

Germline homologous recombination repair (gHRR) variants in bladder cancer: Preliminary evidence and clinical implications
by: Rodolfo Hurle, et al.
Published: (2025)

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm
by: Alan Priester, et al.
Published: (2024)

Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
by: Jeremy Cheng, et al.
Published: (2025)

Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
by: Eric Margolis, et al.
Published: (2025)

Haematuria cancer risk score as a predictor of muscle‐invasive bladder cancer
by: Serdar Turan, et al.
Published: (2025)

The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care
by: Kunal K. Sindhu, et al.
Published: (2024)

Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies
by: Laurence Klotz, et al.
Published: (2024)

The impact of pre‐biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review
by: Abel Tesfai, et al.
Published: (2024)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
by: Jennifer Dunsmore, et al.
Published: (2024)

Incorporating the NICE Cambridge Prognostic Groups and Predict Prostate into a structured informed‐decision making clinic reduces over‐treatment rates of early prostate cancer
by: Vincent J. Gnanapragasam, et al.
Published: (2025)

Long non‐coding RNAs define favourable biology in high‐risk non‐muscle‐invasive bladder cancer
by: Rachel Weng, et al.
Published: (2025)

Cost‐effectiveness analysis of a biopsy‐free diagnostic strategy for prostate cancer using mpMRI and PSMA‐PET/CT
by: Joshua Yi Min Tung, et al.
Published: (2026)

Multiparametric‐magnetic resonance imaging (mp‐MRI) of the prostate and Urolift: Identifying artefact size, location and clinical implications
by: Cameron James Parkin, et al.
Published: (2024)

First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
by: See‐Tong Pang, et al.
Published: (2025)

Penile cancer in French Guiana: Epidemiology, histopathology and clinical aspects
by: Khalil Chalhoub, et al.
Published: (2025)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
by: Nicole Handa, et al.
Published: (2025)

Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
by: Mohammadmehdi Adhami, et al.
Published: (2026)

Long‐term outcome of transurethral laser ablation for recurrent non‐muscle invasive bladder cancer: An EORTC risk‐matched study
by: Chase Peng Yun Ng, et al.
Published: (2025)

Patient experience of bladder cancer: A data linkage study
by: Snehadhar Shah, et al.
Published: (2024)

Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
by: Yuki Teramoto, et al.
Published: (2026)

Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer
by: Mohammed Al‐Zubaidi, et al.
Published: (2024)

Emerging tools for the early detection of prostate cancer
by: Muhammad Haider, et al.
Published: (2025)

Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities
by: Sophia M. Abusamra, et al.
Published: (2025)

Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
by: Esther H. J. Hamoen, et al.
Published: (2025)

Increased risk of bleeding during and after HoLEP in patients with prostate cancer: A multicentre comparative cohort study
by: Angelo Porreca, et al.
Published: (2025)

Bibliometric analysis of focal therapy in prostate cancer research
by: Mohammed Shahait, et al.
Published: (2024)

Extended versus limited pelvic lymph node dissection and long‐term outcomes in high‐risk prostate cancer before radiotherapy
by: Georgios Daouacher, et al.
Published: (2026)

Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia
by: Alison Hiong, et al.
Published: (2025)

Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker
by: Liwu Guo, et al.
Published: (2024)

Comparison of staging MRI to re‐resection for localised bladder cancer: Narrative review
by: Hugo Klempfner, et al.
Published: (2024)

Predictors of adherence to surveillance cystoscopy for patients with non‐muscle invasive bladder cancer
by: Katherina Y. Chen, et al.
Published: (2026)

Understanding symptom contribution to sex inequality in bladder and renal cancer stage at diagnosis
by: Yin Zhou, et al.
Published: (2024)